In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exact Sciences grosses $8.2mm through private placement

Executive Summary

Molecular diagnostics company Exact Sciences grossed $8.2mm through the private sale of 4.3mm common shares at $1.90 each (market average) to undisclosed accredited investors. Concurrently, the company also announced a collaboration with the Mayo Clinic that grants Exact exclusive rights to certain noninvasive colorectal cancer screening IP.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies